XML 25 R13.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Revenue from Contracts with Customers | 9 Months Ended
--- | ---
Sep. 30, 2018
Revenue from Contract with Customer [Abstract] |
Revenue from Contract with Customers | Revenue from Contracts with Customers. We sell our medical products through a direct sales force in the U.S. and through OEM relationships, custom procedure tray manufacturers and a combination of direct sales force and independent distributors in international markets. Revenue is recognized when a customer obtains control of promised goods based on the consideration we expect to receive in exchange for these goods. This core principle is achieved through the following steps: Identify the contract with the customer. A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods to be transferred and identifies the payment terms related to these goods, (ii) the contract has commercial substance and, (iii) we determine that collection of substantially all consideration for services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration. We do not have significant costs to obtain contracts with customers. For commissions on product sales, we have elected the practical expedient to expense the costs as incurred if the amortization period would have been one year or less. Identify the performance obligations in the contract. Generally, our contracts with customers do not include multiple performance obligations to be completed over a period of time. Our performance obligations generally relate to delivering single-use medical products to a customer, subject to the shipping terms of the contract. Limited warranties are provided, under which we typically accept returns and provide either replacement parts or refunds. We do not have significant returns. We do not typically offer extended warranty or service plans. Determine the transaction price. Payment by the customer is due under customary fixed payment terms, and we evaluate if collectability is reasonably assured. None of our contracts as of September 30, 2018 contained a significant financing component. Revenue is recorded at the net sales price, which includes estimates of variable consideration such as product returns, rebates, discounts, and other adjustments. The estimates of variable consideration are based on historical payment experience, historical and projected sales data, and current contract terms. Variable consideration is included in revenue only to the extent that it is probable that a significant reversal of the revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenues. Allocate the transaction price to performance obligations in the contract. We typically do not have multiple performance obligations in our contracts with customers. As such, we recognize revenue upon transfer of the product to the customer's control at contractually stated pricing. Recognize revenue when or as we satisfy a performance obligation. We satisfy performance obligations at a point in time upon either shipment or delivery of goods, in accordance with the terms of each contract with the customer. We do not have significant service revenue. Disaggregation of Revenue The disaggregation of revenue is based on type of product and geographical region. For descriptions of our product offerings and segments, see Note 12 in our 2017 Form 10-K. The following tables present revenue from contracts with customers for the three and nine-month periods ended September 30, 2018 and 2017 (in thousands):
| Three Months Ended September 30, 2018 |  |  |  |  |  | Three Months Ended September 30, 2017 |  |  |  |
| United States |  | International |  | Total |  | United States |  | International |  | Total
Cardiovascular |  |  |  |  |  |  |  |  |  |  |
Stand-alone devices | $ | 52,173 |  | $ | 38,802 |  | $ | 90,975 |  | $ | 36,383 |  | $ | 32,366 |  | $ | 68,749
Custom kits and procedure trays | 23,199 |  | 9,896 |  | 33,095 |  | 23,085 |  | 7,326 |  | 30,411
Inflation devices | 7,819 |  | 15,074 |  | 22,893 |  | 8,241 |  | 11,792 |  | 20,033
Catheters | 18,081 |  | 22,510 |  | 40,591 |  | 15,377 |  | 16,374 |  | 31,751
Embolization devices | 5,145 |  | 7,250 |  | 12,395 |  | 5,414 |  | 6,838 |  | 12,252
CRM/EP | 10,462 |  | 1,739 |  | 12,201 |  | 8,202 |  | 1,325 |  | 9,527
Total | 116,879 |  | 95,271 |  | 212,150 |  | 96,702 |  | 76,021 |  | 172,723
Endoscopy |  |  |  |  |  |  |  |  |  |  |
Endoscopy devices | 9,229 |  | 280 |  | 9,509 |  | 6,389 |  | 225 |  | 6,614
Total | $ | 126,108 |  | $ | 95,551 |  | $ | 221,659 |  | $ | 103,091 |  | $ | 76,246 |  | $ | 179,337
| Nine Months Ended September 30, 2018 |  |  |  |  |  | Nine Months Ended September 30, 2017 |  |  |  |
| United States |  | International |  | Total |  | United States |  | International |  | Total
Cardiovascular |  |  |  |  |  |  |  |  |  |  |
Stand-alone devices | $ | 147,125 |  | $ | 119,592 |  | $ | 266,717 |  | $ | 109,750 |  | $ | 93,709 |  | $ | 203,459
Custom kits and procedure trays | 69,184 |  | 31,175 |  | 100,359 |  | 68,823 |  | 22,259 |  | 91,082
Inflation devices | 23,647 |  | 45,970 |  | 69,617 |  | 24,257 |  | 35,072 |  | 59,329
Catheters | 50,055 |  | 63,775 |  | 113,830 |  | 46,529 |  | 47,828 |  | 94,357
Embolization devices | 15,272 |  | 22,434 |  | 37,706 |  | 16,548 |  | 20,388 |  | 36,936
CRM/EP | 31,058 |  | 5,105 |  | 36,163 |  | 28,212 |  | 3,765 |  | 31,977
Total | 336,341 |  | 288,051 |  | 624,392 |  | 294,119 |  | 223,021 |  | 517,140
Endoscopy |  |  |  |  |  |  |  |  |  |  |
Endoscopy devices | 24,269 |  | 843 |  | 25,112 |  | 19,195 |  | 620 |  | 19,815
Total | $ | 360,610 |  | $ | 288,894 |  | $ | 649,504 |  | $ | 313,314 |  | $ | 223,641 |  | $ | 536,955

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -URI http://asc.fasb.org/topic&trid=49130388 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -URI http://asc.fasb.org/topic&trid=2122369 + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration